What is Innospec Inc.'s earnings per share (EPS)?

Innospec Inc. (IOSP) reported diluted earnings per share of $4.67 for fiscal year 2025. This represents a 228.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Innospec Inc. (IOSP) Financials

IOSP

Trailing 12 months to June 30, 2026

Revenue $1.8B +2.9% YoY

Net Income $121.5M +529.5% YoY

EPS (Diluted) $4.90 +528.2% YoY

Operating Cash Flow $124.3M -9.9% YoY

Market Cap $2.4B as of Oct 10, 2026

Price / Sales 1.3x on $1.8B revenue, trailing 12 months to June 30, 2026

Price / Earnings 19.4x on $121.5M net income, trailing 12 months to June 30, 2026

Price / Book 1.8x on $1.3B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IOSP SEC filings page.

Innospec Inc. (IOSP) reported $1.8B in revenue over the twelve months to Jun 30, 2026, up 2.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IOSP FY2025 2026-10-03

Innospec remains conservatively financed, but 2025 paired weaker sales with thinner margins and lower cash generation.

By FY2025, debt-to-equity had fallen to 0.4x while the current ratio reached 2.8x, showing a less leveraged, more liquid balance sheet even as operations softened. Operating cash flow fell to $138M in FY2025 from its FY2023 peak, even as net income recovered, indicating earnings improved without restoring the earlier cash-generation pace.

Sales fell from $1.9B in FY2023 to $1.8B in FY2025, while gross margin compressed from 30.3% to 27.7%. That pairing points to weaker economics or mix, rather than scale-driven margin expansion.

The 2024 net margin of 1.9% sat far below its operating margin of 9.6%, so the earnings shock occurred below core operations. By FY2025, net margin recovered to 6.6% even as operating margin eased to 7.3%, separating that one-year earnings hit from the underlying operating trend.

Financial Health Signals

Financial Health Score 51/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Innospec Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Innospec Inc. has an operating margin of 7.3%, meaning the company retains $7 of operating profit per $100 of revenue. This strong profitability earns a score of 71/100, reflecting efficient cost management and pricing power. This is down from 9.6% the prior year.

Growth

Innospec Inc.'s revenue declined 3.7% year-over-year, from $1.8B to $1.8B. This contraction results in a growth score of 18/100.

Leverage

Innospec Inc. carries a low D/E ratio of 0.38, meaning only $0.38 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 65/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 2.79, Innospec Inc. holds $2.79 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 76/100.

Cash Flow

Not available for Innospec Inc., and counted as zero in the overall score.

Returns

Innospec Inc. earns a strong 8.8% return on equity (ROE), meaning it generates $9 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 73/100. This is up from 2.9% the prior year.

Altman Z-Score Safe

5.30

Innospec Inc. scores 5.30, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.4B) relative to total liabilities ($499.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/8

Innospec Inc. passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.19x

For every $1 of reported earnings, Innospec Inc. generates $1.19 in operating cash flow ($138.3M OCF vs $116.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$491.4M

YoY+11.8%

QoQ+8.4%

5Y CAGR+6.7%

10Y CAGR+8.0%

Innospec Inc. generated $491.4M in revenue in Q2 2026. This represents an increase of 11.8% from the same quarter a year earlier. Against the prior quarter it is up 8.4%.

EBITDA

$49.7M

YoY+9.5%

QoQ+7.1%

5Y CAGR+1.0%

10Y CAGR+2.7%

Innospec Inc.'s EBITDA was $49.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 9.5% from the same quarter a year earlier. Against the prior quarter it is up 7.1%.

Net Income

$30.8M

YoY+31.1%

QoQ+1.3%

5Y CAGR+6.6%

10Y CAGR+0.6%

Innospec Inc. reported $30.8M in net income in Q2 2026. This represents an increase of 31.1% from the same quarter a year earlier. Against the prior quarter it is up 1.3%.

EPS (Diluted)

$1.25

YoY+33.0%

QoQ+2.5%

5Y CAGR+6.8%

10Y CAGR+0.6%

Innospec Inc. earned $1.25 per diluted share (EPS) in Q2 2026. This represents an increase of 33.0% from the same quarter a year earlier. Against the prior quarter it is up 2.5%.

Cash & Balance Sheet

Cash & Debt

$250.2M

YoY-6.2%

QoQ-13.5%

5Y CAGR+21.5%

10Y CAGR+5.0%

Innospec Inc. held $250.2M in cash as of Q2 2026; long-term debt is not reported for that period.

Dividends Per Share

$0.84

YoY+10.5%

Innospec Inc. paid $0.84 per share in dividends in Q2 2026. This represents an increase of 10.5% from the same quarter a year earlier.

Shares Outstanding

25M

YoY-0.8%

QoQ0.0%

5Y CAGR0.0%

10Y CAGR+0.3%

Innospec Inc. had 25M shares outstanding in Q2 2026. This represents a decrease of 0.8% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Margins & Returns

Gross Margin

28.1%

YoY+0.1pp

QoQ+0.9pp

5Y change-2.4pp

10Y change-9.4pp

Innospec Inc.'s gross margin was 28.1% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.

Operating Margin

8.1%

YoY+0.3pp

QoQ0.0pp

5Y change-2.4pp

10Y change-4.5pp

Innospec Inc.'s operating margin was 8.1% in Q2 2026, reflecting core business profitability. This is up 0.3 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.

Net Margin

6.3%

YoY+0.9pp

QoQ-0.4pp

5Y change-0.1pp

10Y change-6.4pp

Innospec Inc.'s net profit margin was 6.3% in Q2 2026, showing the share of revenue converted to profit. This is up 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.4 percentage points.

Return on Equity

2.3%

YoY+0.5pp

QoQ0.0pp

5Y change0.0pp

Innospec Inc.'s ROE was 2.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.5 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.

Capital Allocation

R&D Spending

$14.2M

YoY+4.4%

QoQ+7.6%

5Y CAGR+10.5%

10Y CAGR+8.6%

Innospec Inc. invested $14.2M in research and development in Q2 2026. This represents an increase of 4.4% from the same quarter a year earlier. Against the prior quarter it is up 7.6%.

Share Buybacks

$6.4M

YoY-24.7%

QoQ-9.9%

5Y CAGR+100.0%

Innospec Inc. spent $6.4M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 24.7% from the same quarter a year earlier. Against the prior quarter it is down 9.9%.

Capital Expenditures

Not reported for Q2 2026.

IOSP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IOSP quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$1.8B	$1.8B-3.7%	$1.8B-5.3%	$1.9B-0.8%	$2.0B+32.4%	$1.5B+24.3%	$1.2B-21.2%	$1.5B+2.5%	$1.5B+13.0%	$1.3B+47.9%	$883.4M-12.7%	$1.0B+5.3%	$960.9M+17.4%	$818.8M+5.5%	$776.4M+0.3%	$774.4M
Cost of Revenue	$1.3B	$1.3B-1.3%	$1.3B-4.1%	$1.4B-1.4%	$1.4B+31.3%	$1.0B+23.3%	$850.4M-18.8%	$1.0B+0.5%	$1.0B+15.3%	$903.5M+63.9%	$551.1M-17.3%	$666.3M+1.1%	$658.9M+16.9%	$563.6M+4.4%	$540.0M-1.5%	$548.0M
Gross Profit	$505.9M	$492.4M-9.3%	$542.9M-8.2%	$591.1M+0.7%	$586.7M+34.9%	$434.9M+26.9%	$342.7M-26.5%	$466.2M+7.2%	$435.0M+7.9%	$403.3M+21.4%	$332.3M-4.0%	$346.0M+14.6%	$302.0M+18.3%	$255.2M+8.0%	$236.4M+4.4%	$226.4M
R&D Expenses	$52.1M	$51.0M-9.7%	$56.5M+15.3%	$49.0M+26.6%	$38.7M+3.5%	$37.4M+21.0%	$30.9M-12.7%	$35.4M+6.0%	$33.4M+6.4%	$31.4M+23.6%	$25.4M+0.4%	$25.3M+14.0%	$22.2M+4.7%	$21.2M+8.2%	$19.6M+7.1%	$18.3M
SG&A Expenses	$304.0M	$285.1M-6.6%	$305.3M-19.8%	$380.5M+5.5%	$360.7M+35.0%	$267.2M+12.7%	$237.0M-15.6%	$280.9M+7.6%	$261.0M+6.9%	$244.2M+12.7%	$216.7M+4.8%	$206.7M+22.2%	$169.2M+19.1%	$142.1M+19.3%	$119.1M-24.8%	$158.3M
Operating Income	$128.9M	$129.5M-27.2%	$177.9M+10.1%	$161.6M-13.7%	$187.3M+41.8%	$132.1M+292.0%	$33.7M-77.5%	$149.9M+12.3%	$133.5M+6.8%	$125.0M+27.3%	$98.2M-37.2%	$156.3M+38.9%	$112.5M+24.2%	$90.6M-6.1%	$96.5M+104.4%	$47.2M
EBITDA	N/A	$173.1M-21.8%	$221.4M+10.2%	$200.9M-11.7%	$227.4M+30.1%	$174.8M+119.3%	$79.7M-59.6%	$197.5M+7.9%	$183.1M+4.4%	$175.4M+28.7%	$136.3M-28.8%	$191.5M+35.2%	$141.6M+27.6%	$111.0M+2.8%	$108.0M+75.3%	$61.6M
Interest Expense	N/A	$0	$0	$0	$0	$0-100.0%	$800K-83.3%	$4.8M-26.2%	$6.5M-9.7%	$7.2M+176.9%	$2.6M+13.0%	$2.3M-39.5%	$3.8M+65.2%	$2.3M+27.8%	$1.8M-53.8%	$3.9M
Income Tax	$21.0M	$21.5M+283.9%	$5.6M-84.1%	$35.3M-31.6%	$51.6M+24.9%	$41.3M+275.5%	$11.0M-71.2%	$38.2M-18.0%	$46.6M-29.7%	$66.3M+204.1%	$21.8M-33.5%	$32.8M+22.4%	$26.8M+78.7%	$15.0M-43.2%	$26.4M+751.6%	$3.1M
Net Income	$121.5M	$116.6M+227.5%	$35.6M-74.4%	$139.1M+4.6%	$133.0M+42.9%	$93.1M+224.4%	$28.7M-74.4%	$112.2M+32.0%	$85.0M+37.5%	$61.8M-24.0%	$81.3M-32.0%	$119.5M+42.1%	$84.1M+8.1%	$77.8M+16.3%	$66.9M+42.0%	$47.1M
EPS (Basic)	N/A	$4.69+228.0%	$1.43-74.5%	$5.60+4.3%	$5.37+42.1%	$3.78+223.1%	$1.17-74.5%	$4.58+31.6%	$3.48+35.9%	$2.56-24.5%	$3.39-31.7%	$4.96+43.8%	$3.45+4.9%	$3.29+13.8%	$2.89+44.5%	$2.00
EPS (Diluted)	$4.90	$4.67+228.9%	$1.42-74.5%	$5.56+4.5%	$5.32+41.9%	$3.75+223.3%	$1.16-74.4%	$4.54+31.6%	$3.45+36.9%	$2.52-24.3%	$3.33-31.5%	$4.86+43.8%	$3.38+5.0%	$3.22+14.6%	$2.81+46.4%	$1.92
Diluted Shares (Avg)	N/A	25M-0.5%	25M+0.4%	25M+0.2%	25M+0.5%	25M+0.3%	25M+0.2%	25M+0.5%	25M+0.5%	24M+0.2%	24M-0.7%	25M-1.1%	25M+3.0%	24M+1.3%	24M-2.7%	25M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$491.4M+11.8%	$453.2M+2.8%	$455.6M-2.4%	$441.9M-0.3%	$439.7M+1.1%	$440.8M-11.9%	$466.8M-5.6%	$443.4M-4.5%
Cost of Revenue	$353.1M+11.6%	$329.7M+4.4%	$328.2M-0.7%	$325.2M+1.8%	$316.5M+2.7%	$315.7M-8.4%	$330.6M-2.5%	$319.3M-2.3%
Gross Profit	$138.3M+12.3%	$123.5M-1.3%	$127.4M-6.5%	$116.7M-6.0%	$123.2M-2.9%	$125.1M-19.7%	$136.2M-12.5%	$124.1M-9.5%
R&D Expenses	$14.2M+4.4%	$13.2M+3.9%	$11.0M-26.2%	$13.7M+0.7%	$13.6M-2.9%	$12.7M-9.3%	$14.9M-8.0%	$13.6M+17.2%
SG&A Expenses	$84.3M+13.0%	$78.5M+13.3%	$69.3M-12.2%	$71.9M+11.8%	$74.6M+4.2%	$69.3M-23.4%	$78.9M-16.9%	$64.3M-23.2%
Operating Income	$39.7M+15.7%	$36.5M-14.1%	$46.8M+13.9%	$5.9M-87.1%	$34.3M-15.7%	$42.5M-15.8%	$41.1M-7.6%	$45.6M+8.8%
EBITDA	$49.7M+9.5%	$46.4M-13.1%	$56.2M+8.1%	$18.1M-68.1%	$45.4M-12.4%	$53.4M-12.3%	$52.0M-4.9%	$56.7M+9.5%
Income Tax	$10.4M+23.8%	$9.1M-21.6%	$2.9M+109.0%	-$1.4M-112.3%	$8.4M-32.8%	$11.6M-16.5%	-$32.2M-529.3%	$11.4M+37.3%
Net Income	$30.8M+31.1%	$30.4M-7.3%	$47.4M+167.3%	$12.9M-61.4%	$23.5M-24.7%	$32.8M-20.8%	-$70.4M-286.2%	$33.4M-14.8%
EPS (Basic)	$1.25+33.0%	$1.23-6.1%	$1.91+167.7%	$0.52-61.2%	$0.94-24.8%	$1.31-21.1%	-$2.82-285.5%	$1.34-15.2%
EPS (Diluted)	$1.25+33.0%	$1.22-6.9%	$1.91+168.2%	$0.52-60.9%	$0.94-24.2%	$1.31-20.6%	-$2.80-285.4%	$1.33-15.3%
Diluted Shares (Avg)	25M-1.3%	25M-1.0%	N/A	25M-0.8%	25M-0.2%	25M+0.1%	N/A	25M+0.4%

Not reported in any period shown, so not listed: Interest Expense.

IOSP Balance Sheet

IOSP quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.8B+5.6%	$1.7B+1.6%	$1.7B+6.5%	$1.6B+2.1%	$1.6B+12.4%	$1.4B-4.9%	$1.5B-0.3%	$1.5B+4.5%	$1.4B+19.4%	$1.2B+14.9%	$1.0B+2.9%	$999.9M+25.8%	$794.7M+37.2%	$579.4M+1.9%	$568.8M
Current Assets	$1.0B+5.0%	$956.6M+8.0%	$885.7M+1.5%	$872.6M+19.8%	$728.1M+28.6%	$566.2M-10.2%	$630.3M-5.1%	$663.9M+18.2%	$561.5M+27.3%	$441.1M-3.8%	$458.7M+10.7%	$414.2M+1.7%	$407.4M+37.4%	$296.6M-7.4%	$320.3M
Cash & Equivalents	$292.5M+1.1%	$289.2M+42.0%	$203.7M+38.5%	$147.1M+3.7%	$141.8M+34.7%	$105.3M+39.1%	$75.7M-38.5%	$123.1M+36.5%	$90.2M-11.5%	$101.9M-25.6%	$136.9M+229.1%	$41.6M-48.1%	$80.2M+258.0%	$22.4M-70.6%	$76.2M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$4.8M+2.1%	$4.7M-28.8%	$6.6M+29.4%	$5.1M+6.3%	$4.8M
Inventory	$329.3M+9.4%	$301.0M+0.3%	$300.1M-19.6%	$373.1M+34.4%	$277.6M+26.2%	$220.0M-10.1%	$244.6M-1.4%	$248.0M+18.2%	$209.8M+20.7%	$173.8M+8.7%	$159.9M-13.5%	$184.9M+16.4%	$158.9M+14.9%	$138.3M+1.8%	$135.9M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$399.0M+4.3%	$382.5M-4.2%	$399.3M+11.3%	$358.8M-1.5%	$364.3M-1.9%	$371.2M+2.3%	$363.0M-0.5%	$364.9M+0.9%	$361.8M-3.5%	$374.8M+40.2%	$267.4M-3.2%	$276.1M+46.9%	$187.9M+26.1%	$149.0M+5.3%	$141.5M
Total Liabilities	$499.5M-3.7%	$518.6M-7.0%	$557.8M-1.0%	$563.3M+4.7%	$537.9M+18.7%	$453.0M-70.6%	$1.5B+138.2%	$647.9M+5.2%	$615.9M+16.7%	$527.6M+24.2%	$424.7M-12.3%	$484.0M+25.6%	$385.3M+46.8%	$262.4M+16.3%	$225.7M
Current Liabilities	$360.1M-3.0%	$371.4M0.0%	$371.5M-8.5%	$405.8M+20.6%	$336.6M+33.4%	$252.4M-16.8%	$303.5M+2.3%	$296.6M+13.4%	$261.5M+42.8%	$183.1M-11.2%	$206.1M-7.5%	$222.9M+43.3%	$155.6M+5.6%	$147.3M+0.9%	$146.0M
Non-Current Liabilities	$139.4M-5.3%	$147.2M-21.0%	$186.3M+18.3%	$157.5M-21.8%	$201.3M+0.3%	$200.6M-83.8%	$1.2B+252.9%	$351.3M-0.9%	$354.4M+2.9%	$344.5M+57.6%	$218.6M-16.3%	$261.1M+13.7%	$229.7M+99.6%	$115.1M+44.4%	$79.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$58.6M-68.5%	$186.2M-8.1%	$202.6M-21.6%	$258.5M+96.4%	$131.6M-5.3%	$139.0M-2.6%	$142.7M+470.8%	$25.0M-16.7%	$30.0M
Total Equity	$1.3B+9.5%	$1.2B+5.6%	$1.1B+10.5%	$1.0B+0.5%	$1.0B+9.3%	$944.4M+1369.4%	-$74.4M-109.0%	$825.0M+3.9%	$793.9M+21.5%	$653.5M+8.0%	$605.0M+17.3%	$515.9M+26.0%	$409.4M+29.1%	$317.0M-7.6%	$343.1M
Retained Earnings	$1.1B+7.2%	$1.0B-0.3%	$1.0B+11.3%	$924.2M+12.3%	$822.9M+8.5%	$758.6M+0.4%	$755.5M+13.0%	$668.3M+10.5%	$605.0M+7.7%	$561.8M+13.2%	$496.4M+26.7%	$391.8M+22.5%	$319.9M+22.2%	$261.7M+8.4%	$241.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.8B+2.2%	$1.8B+2.5%	$1.8B+5.6%	$1.8B+0.1%	$1.8B+6.2%	$1.8B+2.4%	$1.7B+1.6%	$1.8B+11.1%
Current Assets	$1.0B+5.7%	$999.1M+2.3%	$1.0B+5.0%	$988.8M+2.4%	$969.7M+10.6%	$977.1M+7.0%	$956.6M+8.0%	$965.6M+11.8%
Cash & Equivalents	$250.2M-6.2%	$289.1M-3.6%	$292.5M+1.1%	$270.8M-10.9%	$266.6M+11.0%	$299.8M+11.0%	$289.2M+42.0%	$303.8M+46.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$337.3M+0.1%	$321.5M+1.9%	$329.3M+9.4%	$345.2M+8.1%	$336.8M+7.4%	$315.4M+3.6%	$301.0M+0.3%	$319.3M-3.7%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$398.2M+0.2%	$399.1M+2.8%	$399.0M+4.3%	$399.8M+1.9%	$397.6M+2.4%	$388.4M-2.3%	$382.5M-4.2%	$392.3M+9.6%
Total Liabilities	$495.2M-1.9%	$467.6M-8.1%	$499.5M-3.7%	$496.5M-9.7%	$504.6M0.0%	$508.9M-6.9%	$518.6M-7.0%	$550.1M+12.2%
Current Liabilities	$368.1M+9.1%	$334.8M-6.4%	$360.1M-3.0%	$356.1M-4.6%	$337.4M+1.4%	$357.6M-2.0%	$371.4M0.0%	$373.1M+8.4%
Non-Current Liabilities	$127.1M-24.0%	$132.8M-12.2%	$139.4M-5.3%	$140.4M-20.7%	$167.2M-2.6%	$151.3M-16.7%	$147.2M-21.0%	$177.0M+21.0%
Total Equity	$1.3B+3.7%	$1.3B+6.7%	$1.3B+9.5%	$1.3B+4.3%	$1.3B+8.6%	$1.3B+6.5%	$1.2B+5.6%	$1.2B+10.5%
Retained Earnings	$1.1B+7.3%	$1.1B+6.8%	$1.1B+7.2%	$1.1B-3.7%	$1.1B-2.0%	$1.1B-1.1%	$1.0B-0.3%	$1.1B+10.6%

Not reported in any period shown, so not listed: Accounts Receivable, Long-Term Debt.

IOSP Cash Flow Statement

IOSP quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$124.3M	$138.3M-25.0%	$184.5M-11.0%	$207.3M+153.7%	$81.7M-12.3%	$93.2M-36.1%	$145.9M-9.7%	$161.6M+54.1%	$104.9M+26.8%	$82.7M-21.6%	$105.5M-10.7%	$118.2M+11.2%	$106.3M+73.4%	$61.3M0.0%	$61.3M+76.7%	$34.7M
Depreciation & Amortization	N/A	$43.6M+0.2%	$43.5M+10.7%	$39.3M-2.0%	$40.1M-6.1%	$42.7M-7.2%	$46.0M-3.4%	$47.6M-4.0%	$49.6M-1.6%	$50.4M+32.3%	$38.1M+8.2%	$35.2M+21.0%	$29.1M+42.6%	$20.4M+77.4%	$11.5M-20.1%	$14.4M
Stock-Based Compensation	N/A	$8.1M-4.7%	$8.5M+6.3%	$8.0M+19.4%	$6.7M+52.3%	$4.4M-24.1%	$5.8M-12.1%	$6.6M+34.7%	$4.9M+19.5%	$4.1M+24.2%	$3.3M-10.8%	$3.7M+42.3%	$2.6M+4.0%	$2.5M-19.4%	$3.1M0.0%	$3.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$17.6M+30.4%	$13.5M+22.7%	$11.0M+27.9%	$8.6M+22.9%	$7.0M
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$100.6M+8.4%	$92.8M+84.5%	$50.3M-4.6%	$52.7M+90.3%	$27.7M
Investing Cash Flow	-$73.6M	-$75.1M-21.1%	-$62.0M+44.5%	-$111.8M-165.6%	-$42.1M-16.3%	-$36.2M-21.9%	-$29.7M+4.2%	-$31.0M+12.7%	-$35.5M-19.9%	-$29.6M+85.8%	-$209.1M	N/A	N/A	-$116.1M-65.1%	-$70.3M-557.0%	-$10.7M
Financing Cash Flow	-$66.3M	-$63.9M-81.0%	-$35.3M+9.5%	-$39.0M-15.7%	-$33.7M-68.5%	-$20.0M+77.0%	-$86.8M+51.2%	-$177.9M-391.4%	-$36.2M+45.5%	-$66.4M-195.5%	$69.5M	N/A	N/A	$112.8M+352.3%	-$44.7M+18.7%	-$55.0M
Dividends Paid	N/A	$42.4M+9.3%	$38.8M+10.5%	$35.1M+10.7%	$31.7M+10.1%	$28.8M+12.5%	$25.6M+2.4%	$25.0M+15.2%	$21.7M+16.7%	$18.6M+17.0%	$15.9M+6.7%	$14.9M+11.2%	$13.4M+11.7%	$12.0M-74.3%	$46.7M	$0
Share Buybacks	$24.1M	$23.9M+3314.3%	$700K-36.4%	$1.1M-81.4%	$5.9M+637.5%	$800K-61.9%	$2.1M-12.5%	$2.4M+71.4%	$1.4M+27.3%	$1.1M-86.9%	$8.4M-45.1%	$15.3M+121.7%	$6.9M+86.5%	$3.7M+164.3%	$1.4M-95.0%	$28.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$7.2M-31.4%	$17.6M-37.8%	$61.4M+138.9%	$38.1M-48.2%	$10.5M+123.4%	$28.3M-64.9%	$25.7M-64.5%	$73.5M+26.5%
Depreciation & Amortization	$10.0M-9.9%	$9.9M-9.2%	$9.4M-13.8%	$12.2M+9.9%	$11.1M0.0%	$10.9M+4.8%	$10.9M+6.9%	$11.1M+12.1%
Stock-Based Compensation	$4.9M+96.0%	$1.6M-15.8%	N/A	$1.6M-44.8%	$2.5M-32.4%	$1.9M-9.5%	N/A	$2.9M
Investing Cash Flow	-$16.5M-1.9%	-$13.7M+11.6%	-$19.2M+6.8%	-$24.2M-106.8%	-$16.2M-5.2%	-$15.5M-8.4%	-$20.6M+63.1%	-$11.7M+29.9%
Financing Cash Flow	-$29.5M+1.3%	-$6.6M-73.7%	-$20.6M-15.7%	-$9.6M-1166.7%	-$29.9M-58.2%	-$3.8M-860.0%	-$17.8M+12.7%	$900K+350.0%
Dividends Paid	$22.7M+9.1%	N/A	$21.6M+9.1%	$0	$20.8M+9.5%	N/A	$19.8M+10.6%	$0
Share Buybacks	$6.4M-24.7%	$7.1M+47.9%	$0	$10.6M	$8.5M+2733.3%	$4.8M+1100.0%	$0-100.0%	$0

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow.

IOSP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IOSP quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	27.7%-1.7pp	29.4%-0.9pp	30.3%+0.5pp	29.9%+0.6pp	29.3%+0.6pp	28.7%-2.1pp	30.8%+1.4pp	29.4%-1.4pp	30.9%-6.8pp	37.6%+3.4pp	34.2%+2.7pp	31.4%+0.3pp	31.2%+0.7pp	30.4%+1.2pp	29.2%
Operating Margin	7.3%-2.4pp	9.6%+1.3pp	8.3%-1.2pp	9.5%+0.6pp	8.9%+6.1pp	2.8%-7.1pp	9.9%+0.9pp	9.0%-0.5pp	9.6%-1.6pp	11.1%-4.3pp	15.4%+3.7pp	11.7%+0.6pp	11.1%-1.4pp	12.4%+6.3pp	6.1%
Net Margin	6.6%+4.6pp	1.9%-5.2pp	7.1%+0.4pp	6.8%+0.5pp	6.3%+3.9pp	2.4%-5.0pp	7.4%+1.7pp	5.8%+1.0pp	4.7%-4.5pp	9.2%-2.6pp	11.8%+3.0pp	8.8%-0.8pp	9.5%+0.9pp	8.6%+2.5pp	6.1%
Return on Equity	8.8%+5.9pp	2.9%-9.2pp	12.1%-0.7pp	12.8%+3.8pp	9.0%+6.0pp	3.0%	N/A	10.3%+2.5pp	7.8%-4.7pp	12.4%-7.3pp	19.8%+3.5pp	16.3%-2.7pp	19.0%-2.1pp	21.1%+7.4pp	13.7%
Return on Assets	6.4%+4.3pp	2.1%-6.1pp	8.2%-0.1pp	8.3%+2.4pp	5.9%+3.9pp	2.1%-5.6pp	7.6%+1.9pp	5.8%+1.4pp	4.4%-2.5pp	6.9%-4.7pp	11.6%+3.2pp	8.4%-1.4pp	9.8%-1.8pp	11.6%+3.3pp	8.3%
Current Ratio	2.79+0.2x	2.58+0.2x	2.38+0.2x	2.150.0x	2.16-0.1x	2.24+0.2x	2.08-0.2x	2.24+0.1x	2.15-0.3x	2.41+0.2x	2.23+0.4x	1.86-0.8x	2.62+0.6x	2.01-0.2x	2.19
Debt-to-Equity	0.38-0.1x	0.43-0.1x	0.49-0.1x	0.540.0x	0.52+0.5x	0.00	N/A	0.230.0x	0.26-0.1x	0.40+0.2x	0.22-0.1x	0.27-0.1x	0.35+0.3x	0.080.0x	0.09
Asset Turnover	0.97-0.1x	1.06-0.1x	1.14-0.1x	1.22+0.3x	0.94+0.1x	0.85-0.2x	1.030.0x	1.00+0.1x	0.93+0.2x	0.75-0.2x	0.980.0x	0.96-0.1x	1.03-0.3x	1.340.0x	1.36
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9.9%+0.3pp	9.7%+3.5pp	6.1%-0.6pp	6.8%+3.2pp	3.6%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	28.1%+0.1pp	27.3%-1.1pp	28.0%-1.2pp	26.4%-1.6pp	28.0%-1.2pp	28.4%-2.8pp	29.2%-2.3pp	28.0%-1.6pp
Operating Margin	8.1%+0.3pp	8.1%-1.6pp	10.3%+1.5pp	1.3%-8.9pp	7.8%-1.6pp	9.6%-0.5pp	8.8%-0.2pp	10.3%+1.2pp
Net Margin	6.3%+0.9pp	6.7%-0.7pp	10.4%+25.5pp	2.9%-4.6pp	5.3%-1.8pp	7.4%-0.8pp	-15.1%-22.7pp	7.5%-0.9pp
Return on Equity	2.3%+0.5pp	2.3%-0.3pp	3.6%+9.4pp	1.0%-1.7pp	1.8%-0.8pp	2.6%-0.9pp	-5.8%-9.1pp	2.7%-0.8pp
Return on Assets	1.7%+0.4pp	1.7%-0.2pp	2.6%+6.7pp	0.7%-1.1pp	1.3%-0.5pp	1.8%-0.5pp	-4.1%-6.3pp	1.9%-0.6pp
Current Ratio	2.78-0.1x	2.98+0.3x	2.79+0.2x	2.78+0.2x	2.87+0.2x	2.73+0.2x	2.58+0.2x	2.59+0.1x
Debt-to-Equity	0.370.0x	0.35-0.1x	0.38-0.1x	0.38-0.1x	0.390.0x	0.40-0.1x	0.43-0.1x	0.440.0x
Asset Turnover	0.270.0x	0.250.0x	0.250.0x	0.250.0x	0.240.0x	0.250.0x	0.270.0x	0.250.0x

Not reported in any period shown, so not listed: FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Innospec Inc. IOSP	FY2025	$1.8B	$116.6M	6.6%	$2.4B	51/100
Ingevity Corporation NGVT	FY2025	$1.2B	-$167.1M	-14.3%	$2.4B	58/100
Minerals Technologies Inc MTX	FY2025	$2.1B	-$18.4M	-0.9%	$2.0B	50/100
The Chemours Company CC	FY2025	$5.8B	-$386.0M	-6.7%	$2.0B	16/100
Ashland Inc. ASH	FY2025	$1.8B	-$845.0M	-46.3%	$3.2B	37/100
Quaker Houghton KWR	FY2025	$1.9B	-$2.5M	-0.1%	$2.7B	44/100

Where Innospec Inc. Ranks

Frequently Asked Questions

What is Innospec Inc.'s annual revenue?

Innospec Inc. (IOSP) reported $1.8B in total revenue for fiscal year 2025. This represents a -3.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Innospec Inc.'s revenue growing?

Innospec Inc. (IOSP) revenue declined by 3.7% year-over-year, from $1.8B to $1.8B in fiscal year 2025.

Is Innospec Inc. profitable?

Yes, Innospec Inc. (IOSP) reported a net income of $116.6M in fiscal year 2025, with a net profit margin of 6.6%.

What is Innospec Inc.'s EBITDA?

Innospec Inc. (IOSP) had EBITDA of $173.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Innospec Inc.'s gross margin?

Innospec Inc. (IOSP) had a gross margin of 27.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Innospec Inc.'s operating margin?

Innospec Inc. (IOSP) had an operating margin of 7.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Innospec Inc.'s net profit margin?

Innospec Inc. (IOSP) had a net profit margin of 6.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Innospec Inc. pay dividends?

Yes, Innospec Inc. (IOSP) paid $1.71 per share in dividends during fiscal year 2025.

What is Innospec Inc.'s return on equity (ROE)?

Innospec Inc. (IOSP) has a return on equity of 8.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Innospec Inc.'s operating cash flow?

Innospec Inc. (IOSP) generated $138.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Innospec Inc.'s total assets?

Innospec Inc. (IOSP) had $1.8B in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Innospec Inc. spend on research and development?

Innospec Inc. (IOSP) invested $51.0M in research and development during fiscal year 2025.

Does Innospec Inc. buy back shares?

Yes, Innospec Inc. (IOSP) spent $23.9M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Innospec Inc. have outstanding?

Innospec Inc. (IOSP) had 25M shares outstanding as of fiscal year 2025.

What is Innospec Inc.'s current ratio?

Innospec Inc. (IOSP) had a current ratio of 2.79 as of fiscal year 2025, which is generally considered healthy.

What is Innospec Inc.'s debt-to-equity ratio?

Innospec Inc. (IOSP) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Innospec Inc.'s return on assets (ROA)?

Innospec Inc. (IOSP) had a return on assets of 6.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Innospec Inc.'s P/E ratio?

Innospec Inc. (IOSP) trades at 19.4x earnings, its market capitalization divided by net income of $121.5M net income, trailing 12 months to June 30, 2026. The market capitalization is $2.4B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Innospec Inc.'s price-to-sales ratio?

Innospec Inc. (IOSP) trades at 1.3x sales, its market capitalization divided by revenue of $1.8B revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.4B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Innospec Inc.'s Altman Z-Score?

Innospec Inc. (IOSP) has an Altman Z-Score of 5.30, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Innospec Inc.'s Piotroski F-Score?

Innospec Inc. (IOSP) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Innospec Inc.'s earnings high quality?

Innospec Inc. (IOSP) has an earnings quality ratio of 1.19x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Innospec Inc.?

Innospec Inc. (IOSP) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.